XENE Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2022

Xenon Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2022

BURNABY, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in a fireside chat presentation and one-on-one investor meetings at the William Blair Biotech Focus Conference 2022 to be held July 12-13, 2022 in New York, NY.

A webcast of the fireside chat company presentation is available on the “” section of Xenon's website at .

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit .

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:

Jodi Regts

Xenon Pharmaceuticals Inc.

Phone: 604.484.3353

Email:



EN
11/07/2022

Underlying

XENEXenon Pharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Xenon Pharmaceuticals Inc

 PRESS RELEASE
Free
XENE Xenon Pharmaceu...

Xenon Announces Appointment of Darren Cline as Chief Commercial Office...

Xenon Announces Appointment of Darren Cline as Chief Commercial Officer Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications VANCOUVER, British Columbia and BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Darren Cline as Chief Commerci...

June 24, 2025 1 EN
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
XENE XENON PHARMACEUTICALS INC
SAGE SAGE THERAPEUTICS INC.
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
06/20/25 June 20, 2025 1 EN
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
XENE XENON PHARMACEUTICALS INC
SAGE SAGE THERAPEUTICS INC.
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
06/13/25 June 13, 2025 1 EN
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
XENE XENON PHARMACEUTICALS INC
SAGE SAGE THERAPEUTICS INC.
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
06/06/25 June 6, 2025 1 EN
 PRESS RELEASE
Free
XENE Xenon Pharmaceu...

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Co...

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference taking place in Miami, FL, from June 9-11, 2025. Fireside Chat Presentation Details:  Date:Tuesday, June 10, 2025  Time:3:20-3:55 PM Eastern...

June 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch